Glaxo's Advair Is the $100 Billion Asthma Drug That Won't Die

Since 2001, Advair has helped children and adults with chronic lung diseases while raking in about $100 billion in sales for Glaxo along the way. Yet eight years after the patent on the drug itself expired and two years since its companion Diskus inhaler lost exclusivity, it remains untouched by competition from generics in the U.S.